Viridian Therapeutics
VRDN
29.96
-1.48
-4.71%
Viridian Therapeutics
US · VRDN
#2731 by market cap
Listed 1970
29.96
-1.48
-4.71%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Quant vs Street three independent views, side by side
StockVane factor grade
B-
Momentum strategy signal
Hold
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: Wells Fargo moved from Hold to Buy on 2026-06-29.
Analyst consensus 8 analysts
Buy
Avg price target 40.43 +34.9%
Price target rangecurrent 29.96
Low33.00
Avg40.43
High53.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-09 | Wells Fargo | -- | Buy | 39.00 |
| 2026-11-09 | H.C. Wainwright | -- | Buy | 40.00 |
| 2026-11-05 | Wells Fargo | -- | Buy | 34.00 |
| 2026-11-05 | Wedbush | -- | Buy | 42.00 |
| 2026-11-05 | Evercore | -- | Buy | 33.00 |
| 2026-11-05 | H.C. Wainwright | -- | Buy | 40.00 |
| 2026-11-05 | RBC Capital | -- | Buy | 41.00 |
| 2026-11-04 | Wedbush | -- | Buy | 42.00 |
| 2026-11-04 | Goldman Sachs | -- | Buy | 53.00 |
| 2026-11-03 | Wedbush | -- | Buy | 41.00 |
| 2026-10-30 | Evercore | -- | Buy | 26.00 |
| 2026-10-14 | Wells Fargo | -- | Buy | 31.00 |
| 2026-10-08 | RBC Capital | -- | Buy | 38.00 |
| 2026-10-02 | LifeSci Capital | -- | Buy | 35.00 |
| 2026-09-22 | RBC Capital | -- | Buy | 38.00 |
| 2026-09-01 | Truist Financial | -- | Buy | -- |
| 2026-08-19 | Goldman Sachs | -- | Buy | 40.00 |
| 2026-08-13 | Stifel | -- | Buy | 40.00 |
| 2026-08-11 | Truist Financial | -- | Buy | 39.00 |
| 2026-08-10 | Evercore | -- | Buy | 26.00 |
| 2026-08-07 | Truist Financial | -- | Buy | 39.00 |
| 2026-08-06 | TD Cowen | -- | Buy | -- |
| 2026-08-06 | LifeSci Capital | -- | Buy | 35.00 |
| 2026-08-06 | William Blair | -- | Buy | -- |
| 2026-08-06 | Wedbush | -- | Buy | 41.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-06-29 | Wells Fargo | Hold → Buy | 31.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-04 | -- | ±17.64% | +15.53% (in line) |
| 2024/Q1 | 2024-05-08 | -- | ±13.14% | -1.59% (in line) |
| 2023/Q1 | 2023-05-09 | After close | ±22.78% | -1.21% (in line) |
| 2022/Q4 | 2023-03-08 | -- | ±15.86% | -10.48% (in line) |
| 2022/Q3 | 2022-11-14 | -- | ±19.94% | -0.93% (in line) |
| 2022/Q2 | 2022-08-15 | -- | -- | +49.36% |
| 2022/Q1 | 2022-05-12 | -- | ±11.36% | +28.03% (beat) |
| 2021/Q4 | 2022-03-10 | -- | ±23.63% | +5.46% (in line) |
| 2020/Q4 | 2021-03-25 | After close | -- | +4.75% |
| 2020/Q2 | 2020-08-05 | -- | -- | -6.84% |
| 2020/Q1 | 2020-05-07 | -- | -- | +7.27% |
| 2019/Q4 | 2020-03-11 | After close | -- | -16.65% |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Viridian Therapeutics discussion 0 comments